United-Guardian Competitors

Frequency Therapeutics (NASDAQ:FREQ) and United-Guardian (NASDAQ:UG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Earnings and Valuation

This table compares Frequency Therapeutics and United-Guardian's revenue, earnings per share (EPS) and valuation.

United-Guardian has lower revenue, but higher earnings than Frequency Therapeutics.

Risk & Volatility

Frequency Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, United-Guardian has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.

Insider & Institutional Ownership

57.5% of Frequency Therapeutics shares are held by institutional investors. Comparatively, 26.1% of United-Guardian shares are held by institutional investors. 15.4% of Frequency Therapeutics shares are held by company insiders. Comparatively, 29.5% of United-Guardian shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Frequency Therapeutics and United-Guardian's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Frequency Therapeutics and United-Guardian, as provided by MarketBeat.

Frequency Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 359.63%. Given Frequency Therapeutics' higher possible upside, equities analysts clearly believe Frequency Therapeutics is more favorable than United-Guardian.

United-Guardian (NASDAQ:UG) and Alpine Immune Sciences (NASDAQ:ALPN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Alpine Immune Sciences' revenue, earnings per share and valuation.

United-Guardian has higher revenue and earnings than Alpine Immune Sciences.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 52.9% of Alpine Immune Sciences shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 76.1% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Alpine Immune Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Alpine Immune Sciences, as reported by MarketBeat.com.

Alpine Immune Sciences has a consensus price target of $19.40, suggesting a potential upside of 68.99%. Given Alpine Immune Sciences' higher possible upside, analysts plainly believe Alpine Immune Sciences is more favorable than United-Guardian.

United-Guardian (NASDAQ:UG) and Eiger BioPharmaceuticals (NASDAQ:EIGR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Eiger BioPharmaceuticals' revenue, earnings per share and valuation.

United-Guardian has higher revenue and earnings than Eiger BioPharmaceuticals.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Eiger BioPharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 68.8% of Eiger BioPharmaceuticals shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 5.8% of Eiger BioPharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Eiger BioPharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Eiger BioPharmaceuticals, as reported by MarketBeat.com.

Eiger BioPharmaceuticals has a consensus price target of $25.50, suggesting a potential upside of 217.56%. Given Eiger BioPharmaceuticals' higher possible upside, analysts plainly believe Eiger BioPharmaceuticals is more favorable than United-Guardian.

Summary

United-Guardian beats Eiger BioPharmaceuticals on 7 of the 11 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and Impel NeuroPharma (NASDAQ:IMPL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and Impel NeuroPharma's revenue, earnings per share and valuation.

United-Guardian has higher revenue and earnings than Impel NeuroPharma.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and Impel NeuroPharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and Impel NeuroPharma, as reported by MarketBeat.com.

Summary

United-Guardian beats Impel NeuroPharma on 6 of the 6 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and BELLUS Health's revenue, earnings per share and valuation.

United-Guardian has higher revenue and earnings than BELLUS Health.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 38.4% of BELLUS Health shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 24.2% of BELLUS Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and BELLUS Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and BELLUS Health, as reported by MarketBeat.com.

BELLUS Health has a consensus price target of $8.6167, suggesting a potential upside of 149.76%. Given BELLUS Health's higher possible upside, analysts plainly believe BELLUS Health is more favorable than United-Guardian.

Summary

United-Guardian beats BELLUS Health on 7 of the 12 factors compared between the two stocks.

United-Guardian (NASDAQ:UG) and NantHealth (NASDAQ:NH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares United-Guardian and NantHealth's revenue, earnings per share and valuation.

United-Guardian has higher earnings, but lower revenue than NantHealth.

Risk and Volatility

United-Guardian has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, NantHealth has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Institutional & Insider Ownership

26.1% of United-Guardian shares are held by institutional investors. Comparatively, 5.5% of NantHealth shares are held by institutional investors. 29.5% of United-Guardian shares are held by insiders. Comparatively, 59.6% of NantHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares United-Guardian and NantHealth's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for United-Guardian and NantHealth, as reported by MarketBeat.com.

Summary

United-Guardian beats NantHealth on 7 of the 10 factors compared between the two stocks.